Alkermes Buys Rodin TherapeuticsAcquisitions, Alcohol Dependence, Business, CNS Disorders, Deals, FDA, Frontotemporal Dementia (FTD), HDAC-CoREST Inhibitors, Job Cuts, New Drug Applications, Opioid Dependence, Small MoleculesDublin, Ireland-based Alkermes is acquiring Boston-based Rodin Therapeutics for $100 million up front and up to $850 million in milestone payments. Read more November 18, 2019/by BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2019-11-18 12:19:382019-11-18 13:00:01Alkermes Buys Rodin Therapeutics